A visit by the National Security Commission on Emerging Biotechnology (NSCEB) to MIT Lincoln Laboratory put a regional question on the table: how can Massachusetts turn its biotechnology activity into capabilities that support national security? Representatives from state organizations, defense centers, universities, technology companies, and businesses discussed that challenge during the commission’s national roadshow.
Turning a regional ecosystem into national capacity
Biotechnology spans far more than medicines. It includes disease-resistant crops, biofuels, and materials for advanced manufacturing, as well as lifesaving treatments. That breadth connects the field to both economic activity and defense needs.
Congress established NSCEB in 2022 to examine biotechnology’s national security implications and recommend policies that support continued U.S. leadership. In April 2025, its 11-member bipartisan and bicameral commission released a report calling for at least $15 billion in federal investment over five years. The report said China is investing aggressively to dominate the field, a pattern it compared with competition in semiconductors.
Now in the final year of its three-year mandate, the commission is visiting local biotechnology ecosystems and plans to bring what it learns back to Washington. The goal is to help members of Congress support the strengths found in different regions.
Massachusetts links defense strategy with biotechnology
The state has named biotechnology a priority technology area within its Strategic Hub for Innovation, Exchange, and Leadership in Defense (SHIELD) initiative. Launched by Governor Maura Healey in October 2025 with $47 million of initial aligned investment, SHIELD includes the BioNexus program, which uses state matching funds to develop biotechnology and biomanufacturing solutions for the U.S. Army Combat Capabilities Development Command (DEVCOM).
Governor Healey also included a $100 million authorization for defense sector capital projects in the Mass Wins Act, an economic development bill filed in April. The state legislature is considering the bill. More than 40 partner organizations are participating in SHIELD, spanning life sciences, manufacturing, defense, and other fields.
At the roadshow, a panel led by Ben Linville-Engler, co-chair of the SHIELD Working Group and deputy director of the Massachusetts Technology Collaborative, discussed the state’s broad defense and biotechnology base. The article reports $48.6 billion in defense-sector economic contributions for the state last year. Linville-Engler emphasized that the effort reaches beyond Boston and Cambridge to the entire state.
BioSHIELD aims to close the scale-up gap
A central proposal is the Biotechnology Scale-up Hub for Innovation, Economic Development, Labor Training, and Defense (BioSHIELD), a planned 200,000-square-foot biomanufacturing facility in Worcester, Massachusetts. The project is intended to bring industry, academia, and government together to turn research into biological products that can be produced at a larger scale.
The facility is designed to address a difficult transition: early discoveries do not automatically become products that can be manufactured for commercial or defense use. BioSHIELD is expected to provide shared equipment, infrastructure, and secure laboratory space to help bridge that “valley of death.” Its support networks are also meant to help innovators navigate technological and regulatory hurdles.
The project coalition includes Massachusetts Biomedical Initiatives, Worcester Polytechnic Institute, Bio Base Europe Pilot Plant, and Lincoln Laboratory. It builds on the Massachusetts TechHubs program in central Massachusetts. The partners have signed a memorandum of understanding, and design workshops are scheduled to begin soon, ahead of funding and construction.
AI adds another layer to the work
Participants also examined how artificial intelligence and biotechnology intersect. Panelists from Boston University, the University of Massachusetts Boston, Massachusetts Life Sciences Center, Parker Institute for Cancer Immunotherapy, Wyss Institute, and Phicil-itate Change discussed the difficulty of collecting and sharing high-quality datasets prepared for AI use.
They also considered ways AI could improve biomanufacturing and therapeutics. Together, those discussions reflect the event’s wider focus: connecting policy, research, production capacity, and regional partnerships so that biotechnology work can translate into practical capabilities.
Lincoln Laboratory brings longstanding biotechnology experience and ties to academic, commercial, and U.S. government laboratories. The event’s participants described collaboration as a way to connect that expertise across Massachusetts and New England, and to help move promising solutions toward use.